Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi, Pilar García-Alfonso, Michael Geissler, Claus-Henning Köhne, Marc Peeters, Timothy Price, Manuel Valladares-Ayerbes, Ying Zhang, Peter Burdon, Julien Taieb, Dominik P Modest, Andrea Sartore-Bianchi, Pilar García-Alfonso, Michael Geissler, Claus-Henning Köhne, Marc Peeters, Timothy Price, Manuel Valladares-Ayerbes, Ying Zhang, Peter Burdon, Julien Taieb, Dominik P Modest
Abstract
Background: In metastatic colorectal cancer (mCRC), there are limited data on associations between early tumor shrinkage (ETS), depth of response (DpR), and patient characteristics.
Methods: Data from patients with RAS wild-type mCRC who had participated in the PRIME (NCT00364013) and PEAK (NCT00819780) studies were analyzed retrospectively. ETS and DpR were assessed by baseline Köhne category/BRAF status (PRIME) and baseline tumor load (pooled PRIME and PEAK).
Results: Analysis populations included 436 to 665 patients. Patients' chances of achieving ETS of 30% or greater were 63.8%, 50.4%, and 41.9% in the low-, medium-, and high-risk Köhne categories, and 21.7% in those with BRAF mutations. Corresponding percentages for the highest DpR classification (71%-100%) were 47.7% (low risk), 23.6% (medium risk), 10.0% (high risk), and 4.2% (BRAF mutant). No clear relationship was observed between baseline tumor load and ETS or DpR. An ETS of 30% or greater and higher DpR values were associated with statistically significant prolongation of median progression-free survival and overall survival.
Conclusion: Patients with mCRC categorized at baseline by the Köhne criteria as high risk or with BRAF mutations have lower chances of achieving an ETS of 30% or greater or a high DpR. Baseline tumor load was not predictive of ETS or DpR. Favorable ETS or DpR is associated with improved progression-free and overall survival.
Keywords: OS; PFS; Panitumumab; Risk; Volume; mCRC.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed